Apogee Therapeutics, Inc.
APGE
$43.32
$1.463.49%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 88.50% | 99.38% | 124.18% | 200.43% | 305.92% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.99% | 133.19% | 144.90% | 143.90% | 183.06% |
| Operating Income | -103.99% | -133.19% | -144.90% | -143.90% | -183.06% |
| Income Before Tax | -98.24% | -116.86% | -109.90% | -72.49% | -100.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -98.34% | -116.88% | -109.90% | -72.49% | -100.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.34% | -116.88% | -109.90% | -72.49% | -100.60% |
| EBIT | -103.99% | -133.19% | -144.90% | -143.90% | -183.06% |
| EBITDA | -532.78% | -- | -- | -- | -- |
| EPS Basic | 35.70% | 56.00% | 72.74% | 87.42% | 66.68% |
| Normalized Basic EPS | 35.73% | 56.00% | 72.74% | 87.41% | 66.68% |
| EPS Diluted | 35.70% | 56.00% | 72.74% | 87.42% | 66.68% |
| Normalized Diluted EPS | 35.73% | 56.00% | 72.74% | 87.41% | 66.68% |
| Average Basic Shares Outstanding | 57.96% | 121.58% | 274.83% | 1,029.79% | 962.67% |
| Average Diluted Shares Outstanding | 57.96% | 121.58% | 274.83% | 1,029.79% | 962.67% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |